A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

Bio2RDF uri

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

http://bio2rdf.org/clinicaltrials:NCT00140621

Bio2RDF identifier

NCT00140621

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00140621

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a multi-center, ...... r the treatment period.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Safety and Efficacy Study of ...... nts With Cardiac Fabry Disease

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00140621 [clinicaltrials_resource:1c390f491b93b6b3d23e43f4a8238e25]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:4651be943833e2e3f35c62d658dba720]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:4c3aab129d95f39880661a8f976fc5a6]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:6907fe6907dae609fc91edea6195e16f]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:e88876601279dda6fbc721d975097590]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:61bada5256699020c240ff1aaa727ed3]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:b44b6a7c7995aded1b5587ac69630789]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 Baseline to Week 156 [clinicaltrials_resource:b7bb1a76ea124c865872a9c98aab9e94]

completion date [clinicaltrials_vocabulary:completion-date]

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]

condition browse [clinicaltrials_vocabulary:condition-browse]

Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Fabry Disease [clinicaltrials_resource:00e24aaffd391fffb7d3ca954363cf05]

country [clinicaltrials_vocabulary:country]

Japan [clinicaltrials_resource:53a577bb3bc587b0c28ab808390f1c9b]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00140621 [clinicaltrials_resource:5c1570d471a5f3b51c5da15aebab6616]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Agalsidase beta [clinicaltrials_resource:f24450e4db11b73cded401d4f963e96d]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

cardiac fabry disease

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Genzyme, a Sanofi Company [clinicaltrials_resource:8c6e8d6b8a19ceb3967bff4897da3764]

location [clinicaltrials_vocabulary:location]

Fujita Health University Hospital [clinicaltrials_resource:4742bc3b2d101b3c2b4a5960b9871f7f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00140621

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Multicenter Open-label Study ...... nts With Cardiac Fabry Disease

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

AGAL03204

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Percent Change From Baseline in Interventricular Septum and Left Ventricular Posterior Wall Thickness at Week 156 [clinicaltrials_resource:NCT00140621/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Medical Monitor [clinicaltrials_resource:7c18913076d441546a167cc2fc7a1dfa]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Japan: Ministry of Health, Labor and Welfare [clinicaltrials_resource:a75e8a126acc7eaa89800256a4cc6422]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00140621 [clinicaltrials_resource:643543c7d3b81e36a37593c13118ec6a]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00140621 [clinicaltrials_resource:831c590ab99b91b8dc9137434f65bab5]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Sanofi [clinicaltrials_resource:26fba9456e1e33d5671ff7055ed23621]

start date [clinicaltrials_vocabulary:start-date]

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00140621 study design [clinicaltrials_resource:78720a138b22444ad3348db4cbf5dfee]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00140621

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00140621

http://www.w3.org/2001/XMLSchema#string